Here’s what happened to Heel’s “huge discovery’ in the ‘natural treatment’ of Alzheimer’s.

DISCLAIMERS: This is not intended as medical advice or a promotion for any product of any kind. If you have a physical or mental problem, consult an appropriate health practitioner or medical doctor.  At the time of this writing the author has no conflict of interest and no financial interests, or contact with Biologische Heilmittel Heel GmbH, Heel, their holding company, or the owner, inventors agents or employees of or for the aforementioned companies.

Sunday 092213: The Atlantic Black Star reported today ‘a huge discovery’ in the ‘natural treatment’ of Alzheimer’s disease. The story, the Star says, was “recently reported at the Neuroscience Conference in Washington.”

However, a Google search shows that the neuroscience conference referenced by the Star was almost two years ago. In a November 23rd, 2011 Business Wire (BW) press release, BW reports “Heel presented latest studies on a multitarget medication based on low dose natural substances that has proven to positively influence both symptoms as well as disease-related mechanisms of Alzheimer’s.” The press release doesn’t say what the multitarget medication is, either by brand or wha the ‘natural’ content is.

Dr. Bernd Seilheimer of Biologische Heilmittel Heel GmbH (Heel) made the presentation at the neuroscience conference. Seilheimer is one of the medicine’s two inventors.  Heel is a producer of low dose natural substances as used in “homeopathic mixology,” the use of composite homeopathic remedies, or compounds, for a specified clinical condition instead of a single remedy for a pattern of symptoms.

BW quotes Seilheimer as saying, “We are fascinated by the results. This homeopathically prepared medication leads to significant changes in the gene networks associated with synaptic function and plasticity. It significantly reduces the gene expression of APP and BACE, responsible for the formation of β-amyloid plaques which hallmark Alzheimer’s disease. Upon treatment, axons of neurons even grew faster and longer than under saline control conditions.”

Heel is a corporation that produces supramolecular* hydrate pharmaceuticals used by medical practitioners homeopathically. Previously referred to as “homeopathic remedies” the pharmaceuticals used in homeopathic medicine have recently been chemically identified as supramolecular hydrate pharmaceuticals.

The 2011 BW release reported that electroencephalographic (EEG) studies indicated strong effects on cognitive functions by a mix of several natural substances in low doses.
“No preventive or curative therapy is available today,” BW said. “The few drugs that have been approved by regulatory agencies offer only a small symptomatic benefit.”

According to Seilheimer, “All studies have confirmed our earlier observations: this medication has proven to enhance the learning and memory performance in a dose-dependent fashion. It showed at least as effective as the Gold Standard at all tested behavioral models. In addition, it is very well-tolerated. No negative side-effects could be documented with the natural preparation. Following the new paradigm, multitarget preparations could become a natural alternative to conventional preparations for treating complex diseases such as Alzheimer’s.”

“Alzheimer’s is a multi-factorial disease,” he said. “This calls for a change in the therapeutic paradigm towards a multitarget approach.”

BW noted Seilheimer was the 2011 Head of Bioregulatory Development at Biologische Heilmittel Heel GmbH in Baden-Baden, Germany).

A search was then conducted on PUBMED to find what published studies there might be that could corroborate the story that Heel had developed a homeopathic compound for the treatment for Alzheimer‘s Disease. None were found. However, PUBMED shows that in 2012 Seilheimer co authored “Effect of Neurexan on the pattern of EEG frequencies in rats,” published by BMC Complement Altern Med.

The “Neurexan” study was for “a multicomponent, low-dose medication” produced by Heel for sleep disorders. No mentioned of a use for Neurexan for Alzheimer’s was made.

A patent search made on the World Property Organization (WIPO) headquartered in Switzerland revealed a patent filed on May 21, 2013 by two German inventors. The patent application reads: “Title of the invention: “COMPOSITION FOR TREATING OR PREVENTING NEURODEGENERATIVE DISORDERS.” Applicants: BIOLOGISCHE HEILMITTEL HEEL GMBH (DE), Bernd Seilheimer (DE) and Kerstin Roska (DE). It lists Seilheimer and Roska as the inventors of the composition: Bernd Seilheimer (DE) and Kerstin Roska (DE).

According to the abstract posted by the World Intellectual Property Organization:

“The present invention is concerned with plant derived pharmaceutically useful compositions. In particular, it relates to a composition for use in treating and/or preventing a neurodegenerative disorder or disease, wherein said composition comprises extracts of Conium … ”


It seems as if Heel is planning to roll out of a new patented homeopathic Alzheimer’s medicine. But there’s a critical problem with this. It is not in Heel’s formula, nor is it in its patenting of homeopathic preparations, nor is it in Heel’s marketing of a homeopathic product to conventional MD’s. These are all good things, these are all positive approaches in Heel‘s unique presentation of homeopathic products.
The problem is that with jealousies and the war of the lancets between allopathy and homeopathy aside, in order for the medical materials used in homeopathy to gain acceptance in mainstream medicine, their physico-chemistry must first be scientifically understood.

Given the expanding data base and growing acceptance in the material sciences of the supramolecular nature of ultra dilute homeopathic medicine, conventional scientific explanations are now becoming available to practitioners and the homeopathic pharmaceutical industry.

Heel  was founded in 1936 by Hans-Heinrich Reckeweg. The company has offices in 40 countries worldwide including the United States where it is located in Albuquerque, NM. Heel is a subsidiary of DELTON AG, a holding company headquartered in Bad Homburg, Germany. Its Pharmaceuticals and Logistics divisions manage the value-creating investment and entrepreneurial activities of its sole shareholder Stefan Quandt.

Of all the present producers of homeopathic medicines, Heel now appears is the most capably situated in the market to present to mainstream medical professionals what the action and physico-chemical distinctions of the supramolecular materials used in homeopathy.

~ ~ ~

 *The identitification of the chemistry of homeopathic medicine as “supramolecular” was first made by John Benneth at Cambridge’s Cavendish Laboratory on Oct. 1, 2010  in a talk entitled “The Supramolecular Chemistry of the Homeopathic Remedy.”

See John Benneth’s milestone 2010 presentation at the Cavendish Laboratory “Beyond the Molecule: The Supramolecular Chemistry of the Homeopathic Remedy”  Power Point Presentation at Audio

SUBSCRIBE NOW to the JOHN BENNETH JOURNAL, and be alerted of new and interesting developments in curative and spiritual medicine.